Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Xencor, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. The company's proprietary XmAb® technology enables the creation of diverse antibody and cytokine structures with improved therapeutic properties. Xencor's pipeline includes multiple clinical-stage candidates targeting a range of indications, developed both internally and through strategic collaborations with leading pharmaceutical companies. They are committed to translating innovative science into life-changing therapies for patients with unmet medical needs.
Serves as the primary hub for Xencor's research and development, clinical operations, corporate administration, and strategic leadership.
Features state-of-the-art laboratory facilities for antibody engineering, protein production, and preclinical research, alongside modern office spaces designed to foster collaboration and innovation.
Xencor fosters a science-driven, innovative, and collaborative work environment. Employees are often passionate about drug discovery and development, with a strong emphasis on teamwork, scientific rigor, and a patient-focused mission.
The Monrovia headquarters is central to Xencor's operations, housing the core scientific and business functions that drive the company's XmAb® technology platform and pipeline development.
While Xencor's primary physical operations and headquarters are in California, USA, its impact is global. The company conducts clinical trials for its therapeutic candidates in multiple countries, collaborating with international research institutions and contract research organizations. Furthermore, Xencor engages in strategic partnerships and licensing agreements with pharmaceutical companies worldwide, extending the reach of its XmAb® technology and drug candidates to a global patient population.
111 West Lemon Avenue
Monrovia
California
USA
Address: 9880 Campus Point Dr, San Diego, CA 92121, USA
To leverage the rich biotech ecosystem, academic collaborations, and specialized workforce available in the San Diego area, enhancing Xencor's R&D capabilities.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Xencor' leadership includes:
Xencor has been backed by several prominent investors over the years, including:
Xencor's core C-suite executive leadership has shown stability over the past 12 months with no major publicly announced departures. There was a key promotion within the senior leadership team.
Discover the tools Xencor uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Xencor commonly uses the [first_initial][last] email format (e.g., jdoe@xencor.com). Other potential formats, though less common, might include [first].[last]@xencor.com.
[first_initial][last]@xencor.com
Format
bdahiyat@xencor.com
Example
90%
Success rate
Xencor Investor Relations • May 7, 2024
Xencor announced its financial results for the first quarter ended March 31, 2024, and provided a corporate update on its clinical programs, including progress with vudalimab and plamotamab, and its XmAb® BAP platform....more
Xencor Investor Relations • April 8, 2024
Xencor presented preclinical data on its XmAb natural killer (NK) cell engager programs at the American Association for Cancer Research (AACR) Annual Meeting 2024, highlighting potent anti-tumor activity and potential for improved safety profiles....more
Xencor Investor Relations • February 27, 2024
Xencor reported its financial results for the fourth quarter and full year ended December 31, 2023, detailing research and development progress, pipeline advancements, and collaborations....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Xencor, are just a search away.